UK Supreme Court issues Warner-Lambert v Actavis ruling

The UK Supreme Court today dismissed Warner-Lambert’s appeal in its pregabalin patent dispute with Actavis, while clarifying the role of plausibility in the sufficiency of patent applications.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Analysis: Kymab’s ‘patent bargain’ clarification and why it matters

25 June 2020 Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.

Big Pharma

Pfizer secures six-month Lyrica extension in US

29 November 2018 The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

Big Pharma

Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

15 November 2018 The UK Supreme Court’s decision in Warner-Lambert v Actavis is disappointing for pharmaceutical innovators, and enforcing second medical use patents may now be more challenging, lawyers have told LSIPR.

More on this story

Biotechnology

Analysis: Kymab’s ‘patent bargain’ clarification and why it matters

25 June 2020 Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.

Big Pharma

Pfizer secures six-month Lyrica extension in US

29 November 2018 The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

Big Pharma

Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers

More on this story

Biotechnology

Analysis: Kymab’s ‘patent bargain’ clarification and why it matters

25 June 2020 Yesterday’s UK Supreme Court decision in Kymab v Regeneron is expected to have profound implications for innovative life sciences companies, according to lawyers.

Big Pharma

Pfizer secures six-month Lyrica extension in US

29 November 2018 The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

Big Pharma

Warner-Lambert v Actavis ‘disappointing’ for innovators: lawyers